Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is moderately bullish: Eight firms cover Odyssey Therapeutics, with six buy ratings, one hold, and one sell. The average 12-month price target is $35.75.
• Shares recently declined 9.1%: ODTX opened at $24.51, compared with a 50-day moving average of $20.98, and has traded between $15.10 and $29.05 over the past year.
• The company remains loss-making: Odyssey reported quarterly EPS of negative $1.74, while analysts forecast a full-year loss of approximately $5.99 per share.

Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $35.75.

A number of equities analysts have issued reports on the company. Wall Street Zen downgraded Odyssey Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 20th. Wedbush assumed coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $30.00 target price for the company. TD Cowen initiated coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued a "buy" rating for the company. Oppenheimer reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Finally, HC Wainwright initiated coverage on shares of Odyssey Therapeutics in a research note on Thursday, August 27th. They set a "buy" rating and a $44.00 target price for the company.

Odyssey Therapeutics Trading Down 9.1%

ODTX stock opened at $24.51 on Thursday. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $29.05. The firm's fifty day moving average price is $20.98. The firm has a market capitalization of $1.18 billion and a price-to-earnings ratio of -3.62.

Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. Research analysts predict that Odyssey Therapeutics will post -5.99 EPS for the current year.

Institutional Trading of Odyssey Therapeutics

A hedge fund recently bought a new stake in Odyssey Therapeutics stock. The Manufacturers Life Insurance Company purchased a new position in shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 32,125 shares of the company's stock, valued at approximately $601,000. The Manufacturers Life Insurance Company owned approximately 0.07% of Odyssey Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.